Merck Serono to Expand Research and Development Presence in China

China's Research and Development Organization Will Become the Fourth Key R&D Hub for Merck Serono Worldwide

Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain

NOVATO, California, November 23 - Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP)
today announced the presentation of clinical trial data on NGX426, the
Company's orally administered, non-opioid, AMPA/kainate receptor antagonist,
at the 12th International Conference on the Mechanisms and Treatment of
Neuropathic Pain, held on November 20-21 in San Francisco. The results of the
study led by Mark Wallace, M.D., Professor of Clinical Anesthesiology at the
Center for Pain Medicine of the University of California at San Diego,
suggested that NGX426 could be effective in a variety of neuropathic pain
states, which are caused by damage to or dysfunction of the peripheral or
central nervous system rather than stimulation of pain receptors.

Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis

Goal of Trial Achieved Demonstrating Potentially Less Frequent Administration Using Lower Daily Dose

BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries

MINNEAPOLIS, November 23 - BridgePoint Medical announced today that it received European CE Mark
(Conformite Europeene) for its coronary and peripheral Chronic Total
Occlusion (CTO) Crossing System comprised of the CrossBoss(TM) CTO Crossing
Catheter and the Stingray(R) CTO Re-Entry System. The BridgePoint System is a
series of interventional catheters that are designed to navigate highly
diseased arteries in preparation for blood flow restoration via angioplasty
and stenting.

Childbirth Slows Progression of MS - Statement

LONDON, November 24 - Following the Journal of Neurology Neurosurgery and Psychiatry paper
concerning the study investigating the effects of childbirth in MS, the MS
Society has produced the following comment:

VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests

SAN DIEGO, November 19 - Accumetrics, Inc., developer of the VerifyNow System, the first
point-of-care method for measuring platelet reactivity, announces that its
market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in
the POPular study, which was presented during a Late Breaking Clinical Trials
session at the American Heart Association's annual Scientific Sessions. The
VerifyNow P2Y12 Test is used to measure the antiplatelet effect of
medications, such as clopidogrel (Plavix(R)), that reduce platelet reactivity
by blocking the platelet P2Y12 receptor.

Teva Launches TevaGrastim(R) (filgrastim)

LEEDS, England, November 18 - Teva UK Limited has signalled its commitment to developing biosimilar
medicines by entering the G-CSF* therapy area. The launch of its proprietary
version of filgrastim, TevaGrastim(R), marks the Company's first biosimilar*,
and represents a major addition to Teva's Hospitals portfolio.

Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation

GOTHENBURG, Sweden, November 18 - Albireo today announced the completion of a phase 1b study showing a
favourable tolerability and safety profile of A3309 in patients with chronic
idiopathic constipation. In addition, the data revealed appropriate efficacy
signals in this patient population. A3309 is a first in class compound
developed for the treatment of chronic idiopathic constipation and
constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these
results, Albireo expects to recruit 180 patients with chronic idiopathic
constipation in a US phase 2b study (www.clinicaltrials.gov) under an
IND recently placed into effect by the FDA.

Hard To Treat Diseases (HTDS) Mellow Hope's H1N1 Influenza A Vaccine Successful Registration in Chile

SHENZHEN, China, November 18 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that they have acquired a Registration
Certificate for Mellow Hope's H1N1 Influenza A Vaccine from the government
of Chile and the first vaccines will ship in a matter of weeks.

/C O R R E C T I O N — Teva UK Ltd/

LEEDS, England, November 18 - In the news release, "Teva Launches TevaGrastim(R) (filgrastim)" issued on
18 Nov 2009 07:00 GMT, by Teva UK Ltd over PR Newswire, due to an omission
made by PR Newswire, we did not specify that this is a black triangle drug.
The headline should have read "Teva
Launches TevaGrastim(R) (Black Triangle Drug) (filgrastim)" rather than
"Teva Launches TevaGrastim(R) (filgrastim)" as incorrectly originally
transmitted by PR Newswire. Also, directional details to an accompanying
photo should have been included in the release. Complete, corrected release
follows:

DnB NOR Partners With MasterCard to Launch Mobile Payment Services Trial in Norway

Extended Functionality of the MasterCard Mobile Over-the-Air Provisioning Service Includes EMV Configuration to Support Maestro(R) PayPass(TM), Maestro Prepaid and the M/Chip(TM) Application

Hard to Treat Diseases' (HTDS) MMR Vaccine Passed the Chinese SFDA's 'First Drug Evaluation'

SHENZHEN, China, November 17 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and
Rubella Combined Vaccine Live) had obtained a "pass" on its First Drug
Evaluation.

New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications

LEIDEN, The Netherlands, November 17 - Top Institute Pharma (TI Pharma) has formed a
consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and
Maastricht University to define new modalities for the treatment of
hypertension (high blood pressure) and associated vascular complications such
as heart and kidney failure, myocardial infarction and stroke. Based on novel
action mechanisms, new drugs may be discovered with the potential to prevent
vascular complications in patients with hypertension: an opportunity to
improve the quality of life for over a billion people worldwide. This
collaboration, involving 3.4 million euros, 9 new research positions, unique
materials and exchange of know-how, is scheduled to last 3 years.

Destination Therapy Trial Data Demonstrate Superiority for HeartMate II(R) Over HeartMate(R) XVE

STUDY SHOWS TWO-YEAR SURVIVAL OF 58 PERCENT AND DRAMATIC IMPROVEMENT IN QUALITY OF LIFE FOR HEARTMATE II PATIENTS

Video: Crestor(R) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study

ORLANDO, Florida, November 17 - JUPITER, which used CRESTOR 20 mg, is the first statin study to
demonstrate a reduction in the risk of cardiovascular (CV) events in women
without established cardiovascular disease (CVD). In this new analysis of
6,801 women from the JUPITER study, rosuvastatin 20 mg reduced CV events by
46% in women without CVD but at increased risk of a cardiovascular event, as
identified by age and elevated hsCRP (p=0.002 vs placebo). This analysis also
showed a 42% reduction in CV events for men without established CVD (p<0.001
vs placebo). These data were presented today at the American Heart
Association Annual Scientific Sessions in Orlando, Florida.

ALK Announces Landmark Asthma Prevention Trial

ALK Today Announced the Initiation of its Landmark GRAZAX(R) Asthma Prevention (GAP) Trial.

Medical Doctors Confirm "Divine Healing" Cases at the 6th International Christian Medical Conference

KIEV, Ukraine, November 16 - The 6th International Christian Medical Conference was held at the
President Hotel on October 30 and 31, 2009 under the auspices of Ukraine
Organizing Committee of WCDN (World Christian Doctors Network), whose founder
and board chairman is Dr. Jaerock Lee, an evangelical pastor and the author
of many Christian titles.

Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition

ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours

LEUVEN, Belgium and LUND, Sweden, November 16 - ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase I
trial of their novel anti-cancer monoclonal antibody TB-403 in patients with
advanced solid tumours. The results were presented at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics in
Boston, U.S. TB-403 was well tolerated with no reported dose limiting
toxicity. These positive data support progression of TB-403 and further
development.

Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial

New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients

Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease

ORLANDO, Florida, November 15 - Results from a new study showed patients with type 2 diabetes mellitus
who also had coronary artery disease (CAD) and received a 60 mg loading dose
and 10 mg maintenance dose of Efient(R) (prasugrel) achieved significantly
greater platelet inhibition compared with a 600 mg loading dose and 150 mg
maintenance dose of clopidogrel (Plavix(R)). These data were presented today
at the American Heart Association 2009 Scientific Sessions.

First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes

ORLANDO, Florida, November 15 - Results from the RecordAF registry (REgistry on Cardiac rhythm
disORDers assessing the control of Atrial Fibrillation), presented today at
the Scientific Sessions of the American Heart Association, show that in
recently diagnosed and actively treated patients with atrial fibrillation
(AF), a rhythm-control strategy provides better short term control of the
arrhythmia versus a rate-control strategy but does not translate into a
reduction in the occurrence of clinical events at 1 year. RecordAF also
confirmed that these patients suffer from a high rate of clinical events,
mainly cardiovascular (CV) hospitalisations.

New Intra-Arrest Cooling Method May Save More Brains During Cardiac Arrest

Study Unveiled at AHA Late Breaking 'Best of Best' Presentation Shows Survival Benefit -

Mersana Therapeutics Publishes Review Article Detailing Advantages of its Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews

Fleximer(R) Conjugate XMT-1001 Demonstrates Prolonged Stable Disease Without Severe Side Effects Associated with Camptothecin or Irinotecan

AMT Successful in Preclinical Treatment of DMD

AMSTERDAM, November 11 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, announced today that it has successfully
treated Duchenne muscular dystrophy (DMD) in an animal model with its
proprietary gene therapy. The proof of concept studies were performed in
collaboration with the group of Professor Irene Bozzoni (University of Rome,
La Sapienza, Italy) and demonstrated effectiveness in the heart as well as in
skeletal muscles. In a previous study, AMT's gene therapy approach was shown
to be successful in the treatment of diseased human muscle cells obtained
from biopsies of DMD patients. These data establish a robust basis for AMT's
therapeutic approach to DMD.

Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence

This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 November 2009.

See the Benefits of a Healthy Lifestyle

ANDOVER, England -

Sight charity The Eyecare Trust has joined forces with healthcare provider Simplyhealth to warn that many lifestyle choices can pose a serious threat to eyesight. As well as alerting people to the eye health risks posed by obesity, the charity is stressing that smoking, poor diet, lack of exercise and excessive alcohol consumption can all dramatically increase the risk of sight loss or even blindness.

Being Bothered About Employee Eye Health

ANDOVER, England -

ANDOVER, England, November 9 /PRNewswire/ –

Over two-fifths (43%) of computer-users are unaware their employer could help them with costs towards eye care, according to a new survey commissioned by sight charity The Eyecare Trust and healthcare provider Simplyhealth for National Eye Week (9-15 November 2009). These findings highlight the need for employers to effectively communicate the support available for employees to help look after their eye health.

Zebinix a Novel Once Daily Anti-Epileptic Launched Today in the UK

LONDON -

- New Option for Adjunctive Treatment of Adult Epilepsy Patients With Partial Onset Seizures Reduces Seizure Frequency and Improves Health-Related Quality of Life

Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment

LONDON - Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

PARIS -

- Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections

Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference

NOVATO, California -

- Proof-of-Concept Data at 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain

Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts

AURORA, Ontario -

Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: HXBPF) announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.

FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease

CAMBRIDGE, Massachusetts -

- FDA Issued Action Date of February 28, 2010 Under the Prescription Drug User Free Act (PDUFA)

MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014

WILMINGTON, Delaware - The new market research report, ‘Global Stem Cell and Advanced Technologies Market’ (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com) analyzes the major trends in the global stem cell market. It identifies and analyzes the main market drivers, restraints, and opportunities for the various products, services, technologies, and applications submarkets in different geographic regions.